OLD Mission Capital LLC Invests in Syneos Health, During 4th Quarter
July 4, 2023
🌥️Trending News
Syneos Health ($NASDAQ:SYNH) is a global biopharmaceutical solutions organization. It provides comprehensive end-to-end clinical and commercial solutions to biopharmaceutical and medical device companies. They combine the strength of full-service clinical solutions with the focus and expertise of specialized consulting services. Syneos Health offers services that include clinical development, clinical operations, biometrics, medical affairs, regulatory affairs, and commercialization. Syneos Health has a proven track record of success, as evidenced by its long list of successful partnerships with leading pharmaceutical companies such as Merck, Daiichi Sankyo, Johnson & Johnson, Novartis, and Pfizer.
In addition to their services, Syneos Health is also committed to making a positive impact in the global healthcare industry by engaging in research initiatives and providing educational opportunities to healthcare professionals. This strategic investment from OLD Mission Capital LLC is likely to further strengthen Syneos Health’s position in the biopharmaceutical industry and drive innovation in healthcare. With this new investment, Syneos Health is well positioned to continue its success and expand its service offerings in the years to come.
Share Price
The stock opened at $42.2 and closed at the same level, increasing by a minuscule 0.2% from its prior closing price of $42.1. This news comes as Syneos Health is nearing the completion of its restructuring process, which has seen a number of cost-saving measures such as reducing labor costs, layoffs, and divesting from non-core businesses. As a result of these changes, the company is now able to focus solely on its core competencies. The new injection of capital is expected to help Syneos Health further its mission of providing clients with a comprehensive suite of services in drug development and commercialization.
Syneos Health remains an attractive investment for those seeking to capitalize on drug development and commercialization services, with high growth potential and a strong outlook for the future. With the injection of capital from Old Mission Capital LLC, Syneos Health will be well-positioned to take advantage of new opportunities and continue its growth. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syneos Health. More…
| Total Revenues | Net Income | Net Margin |
| 5.41k | 148.17 | 4.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syneos Health. More…
| Operations | Investing | Financing |
| 386.52 | -107.76 | -302.39 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syneos Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 8.1k | 4.64k | 33.33 |
Key Ratios Snapshot
Some of the financial key ratios for Syneos Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.7% | 6.0% | 5.2% |
| FCF Margin | ROE | ROA |
| 5.3% | 5.0% | 2.2% |
Analysis
GoodWhale has assessed SYNEOS HEALTH’s fundamentals and concluded that they have a high health score of 8/10. This means that the company is capable to safely ride out any crisis without the risk of bankruptcy, due to its cashflows and debt. We have assessed SYNEOS HEALTH to be strong in stability, medium in growth, profitability and weak in asset, dividend. Given these observations, we classify SYNEOS HEALTH as a ‘sloth’ type of company, which has achieved revenue or earnings growth slower than the overall economy. Given these characteristics, we believe that value investors looking for steady returns may find SYNEOS HEALTH attractive. These investors are typically interested in stocks that are undervalued and can be held for a long time to generate returns. Furthermore, those looking to invest in dividend-paying stocks may also find SYNEOS HEALTH attractive, due to its strong cashflows and debt position. More…
Peers
The company competes with Shin Nippon Biomedical Laboratories Ltd, Icon PLC, and Guardant Health Inc, among a few other companies in the biopharmaceutical services industry. Syneos Health Inc provides an end-to-end solution for customers with deep expertise and a focus on service excellence.
– Shin Nippon Biomedical Laboratories Ltd ($TSE:2395)
Shin Nippon Biomedical Laboratories Ltd, or SNBL, is a Japanese-based company specializing in the development and manufacture of laboratory animal models for the pharmaceutical and medical industries. The company has a market cap of 94.46B as of 2022, which reflects its strong financial performance and industry leadership. Additionally, SNBL has a Return on Equity of 27.97%, indicating a strong return on its investments. SNBL is well-positioned to continue to deliver strong returns for investors and to remain a leader in the laboratory animal model industry.
– Icon PLC ($NASDAQ:ICLR)
Icon PLC, founded in 1977, is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Based in Dublin, Ireland, the company operates in over 30 countries and employs over 11,500 professionals. With a market capitalization of 15.9 billion as of 2022, Icon PLC is one of the largest companies in its space. The company boasts a Return on Equity of 4.96%, indicating a strong level of profitability and efficient use of capital. Icon PLC focuses on providing a wide range of services such as clinical trial management, regulatory affairs outsourcing, safety and pharmacovigilance, biometrics, and medical writing.
– Guardant Health Inc ($NASDAQ:GH)
Guardant Health Inc is a biotechnology company based in Redwood City, California, and is focused on developing non-invasive cancer diagnostics. The company has a market cap of 4.75 billion as of 2022. Guardant Health Inc had a return on equity of -150.22%, which illustrates that the company had a negative profitability from its investments. This suggests that the company has not been able to generate enough profits from its investments to cover its cost of capital and grow its value for shareholders. Although this is not a positive sign for investors, it may be a sign that the company is investing heavily into research and development of new products and technologies that could eventually bring profits in the future.
Summary
Syneos Health, Inc. is a biopharmaceutical solutions company that recently attracted attention from investors. Analysts are bullish on the company’s prospects, as they believe it has a strong outlook. Syneos Health has a number of products and services which have been gaining traction in the industry.
It offers clinical development solutions and commercialization services to biopharmaceutical companies, and has a growing presence in the market. With a strong business model and a promising future, Syneos Health is an attractive investment option for those looking to diversify their portfolios.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
